HYFT

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

News Provided by Biotech Insider on behalf of MindWalk Holdings Corp. BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Biotech Insider News Commentary - For most of the past decade, the promise of AI in drug discovery was measured in designs: more candidate molecules, generated faster. The measure is changing. The companies building AI-native discovery platforms are now being judged on what happens when those designs meet a laboratory bench and then an animal model, the preclinical efficacy stage where a program’s value starts to be defined. That shift is pulling AI companies toward wet-lab capability and experienced development scientists, and much of that talent is concentrated in Greater Bost

Senior appointments from Pfizer, Novartis, Arbor Biotechnologies, and Orum Therapeutics bring preclinical development, structural biology, and portfolio strategy depth as MindWalk prepares its programs for preclinical efficacy studies MindWalk Holdings Corp. (NASDAQ:HYFT) ("MindWalk" or the "Company"), a Bio-Native AI company, today announced three senior appointments that strengthen its Boston-based development leadership as the Company’s pipeline advances toward preclinical efficacy studies. Zachary Maben, PhD, joins as Director, Antigen Discovery & Protein Engineering, from Arbor Biotechnologies and previously Pfizer. Joanne Lim, PhD, joins as Director, Preclinical Development, from Or

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

As data platforms and industry analysts converge on the "ontology layer" as the missing piece of agentic AI, MindWalk outlines why life sciences needs a biological context layer of its own, and why ReefIQ™, powered by HYFT® Technology, is that layer MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today outlined why the ontology layer now being built across enterprise AI does not reach biological function, and why life sciences requires a biological context layer of its own. ReefIQ™, MindWalk's biological context layer for life sciences, supplies what a horizontal ontology cannot: a governed, model-agnostic representation of what biology does, available from th

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Veteran Banker and Licensed Fiduciary to Serve on the Audit Committee and the Compensation, Nomination and Governance Committee MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced the appointment of Kim Remizowski to its Board of Directors as an independent director, effective September 29, 2026. Mr. Remizowski will serve on the Audit Committee and the Compensation, Nomination and Governance Committee. The Board has determined that he qualifies as an independent director under Nasdaq listing rules and as an audit committee financial expert under applicable SEC rules. With this appointment, the Board comprises four directors, three of whom are indep

AUSTIN, Texas, Sept. 22, 2026 (GLOBE NEWSWIRE) -- American News Group News Commentary - For most of the last decade, predicting the three-dimensional shape of a protein complex was the kind of capability only a well-funded research organization could stand up. That is changing quickly. Open-source structure prediction models are now freely licensed for commercial use, and the largest chipmakers are packaging them as ready-to-deploy inference microservices that can be launched from a cloud marketplace. The Business Research Company projects the AI protein structure prediction market will grow from about $2.33 billion in 2026 to roughly $6.62 billion by 2030, a compound annual growth rate of

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Antibody-antigen inference ran approximately 5x faster than in MindWalk's prior environment. The deployment, run with engineering partners AMD and Vultr on AMD Instinct™ MI325X GPUs, demonstrates the model-agnostic architecture and elastic compute beneath ReefIQ™ as MindWalk onboards enterprise partners. MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced results from a production deployment of the open-source OpenFold3 structure prediction model, run with engineering partners AMD and Vultr on Vultr Kubernetes Engine and Vultr Cloud GPU powered by AMD Instinct™ MI325X GPUs and delivered through AMD Inference Microservices (AIM). It also served as a

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

ReefIQ™ launched commercially, and a US$30 million unsecured credit facility commitment, drawn only as needed, adds balance-sheet flexibility with no dilution. MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today reported financial results for its fiscal 2027 first quarter ended July 31, 2026. The quarter marked the commercial launch of ReefIQ™, MindWalk's data platform, and the start of its shift toward recurring, platform-based revenue. Revenue increased 21.3% year over year to $3.8 million. Gross profit increased 47.1% to $2.2 million; gross margin expanded to 58.6% from 48.3%. Net cash used in operating activities declined to $4.0 million from $4

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Facility carries a fixed 7.00% interest rate with no financial maintenance covenants, no warrants or equity conversion features, and no dilution to existing shareholders MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it has entered into a binding commitment with Sanabil (Cayman) for a senior unsecured revolving credit facility of up to US$30 million. The facility is intended to support MindWalk’s biologics programs, commercial expansion, working capital, and general corporate purposes. The facility carries a fixed annual interest rate of 7.00%, accruing only on amounts drawn, and an initial term of 36 months, extendable by 12 months by

MindWalk Holdings Corp. ("MindWalk") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it is participating in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14 - 16, 2026 at the Lotte New York Palace Hotel in New York, where a pre-recorded fireside chat with Chief Executive Officer Dr. Jennifer Bath is available to registered attendees on demand. "The question institutional investors are working through is where durable value sits in biological AI - and our answer is the representation layer, not any single model. A fireside format lets us make that case in the street’s terms and show what it means for the drug developers racing to put AI to work."

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

MindWalk to host an earnings conference call and webcast MindWalk Holdings Corp. ("MindWalk" or the "Company") (NASDAQ:HYFT), a Bio-Native AI company, today announced that it will report financial results for the first quarter of fiscal year 2027 and host a conference call on Monday, September 14, 2026, at 5:00 p.m. Eastern Time. Financial results will be issued in a press release prior to the call, which will include a management presentation followed by a question-and-answer session. Conference Call and Webcast Details Event Date and Time: Monday, September 14, 2026, at 5:00 p.m. Eastern Time The conference call will be webcast live and available for replay via a link provided in

AUSTIN, Texas, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Market Updates News Commentary - Earnings season in life sciences technology has just delivered an unusually clean verdict. The company that owns the industry’s data and systems of record beat and jumped. The company selling model-informed software into the same customers missed and fell by roughly the same amount on the day. The AI-native discovery company reported a fraction of the revenue analysts expected. Read together, those three results say something specific about where value is accruing in AI-enabled drug discovery, and it is not where most of the narrative has been pointed. Companies mentioned in today’s commentary include: Mind

NEW YORK, Aug. 19, 2026 (GLOBE NEWSWIRE) -- USA News Group News Commentary - Artificial intelligence has become the most talked-about tool in drug discovery, promising to compress the years and billions of dollars it takes to turn a biological insight into a medicine. But most of the AI now aimed at biology shares a hidden limitation: it reasons primarily from sequence, the raw genetic letters of DNA, RNA, and proteins. Two molecules whose sequences look alike are treated as related; two that look different are treated as unrelated. That assumption is convenient, and it is often wrong, because biology repeatedly reaches the same function through completely different-looking structures. A c

AUSTIN, Texas, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - Most AI applied to drug discovery works from sequence. Two molecules that look alike in their genetic code are treated as related, and two that do not are treated as unrelated. That assumption is convenient and it is frequently wrong, because biology routinely arrives at the same functional outcome through structures that share no obvious sequence similarity. MindWalk Holdings Corp. (NASDAQ:HYFT) has built its entire technology stack around that gap, and in late July it put the result on a stage in front of the AI infrastructure industry. Three Layers, One Idea MindWalk describes itself as a Bio-Native AI c

EFFECT - MindWalk Holdings Corp. (0001715925) (Filer)

6-K - MindWalk Holdings Corp. (0001715925) (Filer)

Issued on behalf of MindWalk Holdings Corp. (NASDAQ:HYFT)USA News Group News CommentaryNEW YORK, July 23, 2026 /CNW/ -- For years, the promise of artificial intelligence in drug discovery has been easy to describe and hard to monetize. Plenty of companies can talk about accelerating the search for new medicines; far fewer can point to real revenue, real clients, and a business model that compounds. One small-cap AI biotech just put a set of numbers behind its version of that story, and they show a company whose pivot is starting to appear in its financials rather than only in its slide decks. The company reported full-year resu